VGA1155

08/19/2010 - "VGA1155 administration significantly reduced infarct volume and improved neurological scores at 1 week after ischemic injury. "
07/18/2008 - "Anti-VEGF receptor antagonist (VGA1155) reduces infarction in rat permanent focal brain ischemia."
07/18/2008 - "A single dose of VGA1155 (10mg/kg, i.p.) was administered 30 minutes before the induction of MCAO after which brain water content, Evans blue extravasation, neurological score, infarct volumes and VEGF expression determined by means of ELISA were compared with corresponding values for vehicle injected control rats. "
08/19/2010 - "The novel VEGF receptor antagonist, VGA1155, reduces edema, decreases infarct and improves neurological function after stroke in rats."
07/18/2008 - "Brain water content and Evans Blue extravasation 24 hours after ischemia were not significantly reduced, but, compared with control group, VGA1155 significantly reduced infarct volume (32.0% for VGA1155 vs. 46.7% for control; % volume of hemisphere volume) and improved neurological function 7 days after ischemia, when tissue content of the VEGF group markedly increased to nine times that of the vehicle-treated animals. "

08/19/2010 - "With this dose, VGA1155 also reduced vascular permeability from 2.2 ± 0.8 µg/g to 1.2 ± 0.5 µg/g studied at 6 h after the ischemia by intravenous injection of Evans blue. "
08/19/2010 - "In the treatment group, a single dose of VGA1155 (1 ~ 50 mg/kg i.p.) was administrated 30 min before the induction of focal ischemia, and the vehicle group received phosphate buffer only. "
07/18/2008 - "Brain water content and Evans Blue extravasation 24 hours after ischemia were not significantly reduced, but, compared with control group, VGA1155 significantly reduced infarct volume (32.0% for VGA1155 vs. 46.7% for control; % volume of hemisphere volume) and improved neurological function 7 days after ischemia, when tissue content of the VEGF group markedly increased to nine times that of the vehicle-treated animals. "

09/01/2004 - "VGA1155 thus exhibits promise as an antiangiogenic or anti-tumor agent with fewer side-effects."
09/01/2004 - "VGA1155 also inhibited VEGF-induced tube formation of HUVEC in vitro and tumor angiogenesis toward B16-BL6 melanoma after orthotopic implantation into the skin of the back. "
11/01/2005 - "VGA1155 suppressed the growth of human lung, breast, colon and epidermoid cancers (LC-6, HT29, MX-1, Col-1 and A431) in the nude mouse xenograft model, and pulmonary metastasis of melanoma in the spontaneous metastasis model. "

09/01/2004 - "VGA1155 also inhibited VEGF-induced tube formation of HUVEC in vitro and tumor angiogenesis toward B16-BL6 melanoma after orthotopic implantation into the skin of the back. "
11/01/2005 - "VGA1155 suppressed the growth of human lung, breast, colon and epidermoid cancers (LC-6, HT29, MX-1, Col-1 and A431) in the nude mouse xenograft model, and pulmonary metastasis of melanoma in the spontaneous metastasis model. "

07/18/2008 - "VGA1155 was found to protect against secondary ischemic brain damage after permanent focal cerebral ischemia, although it did not reduce vasogenic edema at 24 hours. "
08/19/2010 - "The novel VEGF receptor antagonist, VGA1155, reduces edema, decreases infarct and improves neurological function after stroke in rats."